Selective cytopheresis devices and related methods thereof

Patent metadata

Field	Value
Publication number	US-9498566-B2
Application number	US-201213531872-A
Country	US
Kind code	B2
Filing date	Jun 25, 2012
Priority date	Aug 31, 2007
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

First claim

What is claimed is:

1. A system for treating activated platelets from a subject in need thereof, the system comprising:
a device comprising a housing defining a passageway that permits body fluid from the subject to pass therethrough and a fiber or a plurality of fibers disposed within the housing, wherein each fiber has an exterior surface that binds the platelets; and
a calcium chelating agent comprising citrate present in an amount sufficient to inhibit the release of a pro-inflammatory substance from the activated platelets or to deactivate the platelets.

2. The system of claim 1 , further comprising a second device in series with the device comprising the housing defining the passageway.

3. The system of claim 1 , wherein the calcium chelating agent is infused into the passageway.

4. The system of claim 1 , wherein the surface that binds the platelets comprises a membrane.

5. The system of claim 4 , wherein the membrane is porous.

6. The system of claim 5 , wherein the membrane permits the passage of fluid therethrough.

7. The system of claim 4 , wherein the membrane has a surface area greater than about 0.2 m 2 .

8. The system of claim 4 , wherein a surface of the membrane binds the platelets.

9. The system of claim 1 , wherein the device is configured such that shear force within the passageway is less than about 10 dynes/cm 2 when fluid passes through the passageway at a rate of from about 100 mL/minute to about 500 mL/minute.

10. The system of claim 1 , wherein the exterior surface that binds the platelets comprises a cell-adhesion molecule that binds an activated platelet.

11. The system of claim 1 , wherein the fiber is, or plurality of fibers are, hollow.

12. The system of claim 1 , wherein the device is cell-free.

13. The system of claim 1 , wherein the device is configured to bind the platelets for a time sufficient to permit the subsequent inhibition or release of a pro-inflammatory substance from the platelets and/or deactivation of the platelets.

14. The system of claim 1 , wherein the exterior surface of the fiber binds the platelets.

Assignees

• Humes H David
• Buffington Deborah
• Cytopherx Inc
• Univ Michigan Regents

Inventors

• Humes H David
• Buffington Deborah

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title